License rights and other intangible assets, net

6 Months Ended

Jun. 30, 2021

Goodwill And Intangible Assets Disclosure [Abstract]

License rights and other intangible assets, net

6. License rights and other intangible assets, net

The following provides information about our license rights and other intangible assets, net (in thousands):

	June 30, 2021						December 31, 2020
	Gross						Gross
	Carrying		Accumulated				Carrying		Accumulated
	Amount		Amortization		Net		Amount		Amortization		Net
Intangible assets subject to amortization:
License rights agreement	$	40,000	$	5,313	$	34,687	$	40,000	$	3,803	$	36,197
Hormone therapy drug patents		4,689		901		3,788		4,045		749		3,296
Hormone therapy drug patents    applied and pending approval		1,396		—		1,396		1,629		—		1,629
		46,085		6,214		39,871		45,674		4,552		41,122
Intangible assets not subject to amortization:
Trademarks/trade name rights		335		—		335		323		—		323
License rights and other intangible assets, net	$	46,420	$	6,214	$	40,206	$	45,997	$	4,552	$	41,445

We recorded amortization expense related to the exclusive license rights agreement (the “Population Council License Agreement”) with Population Council of $0.8 million for the three months ended June 30, 2021 and 2020, and $1.5 million for the six months ended June 30, 2021 and 2020.    

As of June 30, 2021 and December 31, 2020, respectively, we had a total of 83 patents, of which 41 were domestic, and a total of 77 patents, of which 38 were domestic.  We recorded amortization expense related to patents of $0.1 million for the three months ended June 30, 2021 and 2020, and $0.2 million and $0.1 million for the six months ended June 30, 2021 and 2020, respectively.  

We use a combination of qualitative and quantitative factors to assess intangible assets for impairment. As a result of performing these assessments, we determined that no impairment existed as of June 30, 2021 and, therefore, recorded no write-downs to any of our intangible assets.